This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Optina (oral)

Ampio Pharmaceuticals, Inc.

Drug Names(s): Low-dose danazol

Description: BioMedTracker has separate drug profiles for the oral and intranasal formulations of Optina. Please also see Optina (intranasal).

Optina is an orally-administered repositioned compound based on a low-dose formulation of approved drug danazol. Danazol was first approved by the FDA in the early 1970’s and is a derivative of the synthetic steroid ethisterone.

Danazol in low doses has the capability to control the permeability of tissues, thus reducing vascular leakage. Vascular permeability is a key endothelial mechanism by which inflammatory cytokines and angiogenic factors affect target cells and organs to mediate the inflammatory response or cell growth. During the disease state, there is an increase in vascular permeability factors leading to vasodilation, edema formation, and disruption of intercellular membrane structure.

Although the mechanism of action of Optina is not fully understood, the company has shown that Optina has multi-targeted, disease-modifying activity that inhibits inflammation, cell proliferation, neovascularization, fibrosis and scarring.


Optina (oral) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug